Brought to you by 
OriGene's Series B brings in $16mm
27 Apr 2010
Executive Summary
OriGene Technologies Inc. (genomics- and proteomics-based research tools for life sciences companies) raised $16mm through its Series B round. IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO led and were joined by existing investors Morningside Venture Investments and President International Development Corp. OriGene will use the proceeds to continue work on its TrueMAB collection of monoclonal antibodies.
Deal Industry
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
OriGene's Series B brings in $16mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice